Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH – Get Free Report) has earned a consensus rating of “Buy” from the seven brokerages that are presently covering the firm, Marketbeat Ratings reports.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company ...

Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) had its price objective lowered by HC Wainwright from $14.00 to $11.00 ...

CUPERTINO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the ...

Fintel reports that on January 10, 2025, Maxim Group upgraded their outlook for Reviva Pharmaceuticals Holdings (NasdaqCM:RVPH) from Hold to Buy. Analyst Price Forecast Suggests 724.68% Upside As ...

Investors with a lot of money to spend have taken a bearish stance on Reviva Pharmaceuticals RVPH. And retail traders should know. We noticed this today when the trades showed up on publicly ...

Latest data shows the largest indicative borrow rate increases among liquid option names include: Snow Lake Resources Ltd. (LITM) 105.23% ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Globus Medical (GMED – Research Report) and Reviva Pharmaceuticals Holdings (RVPH – Research ...